CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
about
Molecules that target nucleophosmin for cancer treatment: an updateProtein kinase CK2 and human malignant tumorsOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.Halogenated imidazole derivatives block RNA polymerase II elongation along mitogen inducible genes.Phage display in molecular imaging and diagnosis of cancer.Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Protein kinase CK2 in health and disease: CK2: a key player in cancer biologyTenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cellsBiophysical Characterization of Nucleophosmin Interactions with Human Immunodeficiency Virus Rev and Herpes Simplex Virus US11.Phage Peptide Libraries As a Source of Targeted Ligands.Identification of a Potent Allosteric Inhibitor of Human Protein Kinase CK2 by Bacterial Surface Display Library Screening.CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.Inhibition of αENaC expression and ENaC activity following blockade of the circadian clock-regulatory kinases CK1δ/ε.Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.Casein kinase: the triple meaning of a misnomer.Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.Casein kinases as potential therapeutic targets.Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB.Protein Kinase CK2: Intricate Relationships within Regulatory Cellular Networks.Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.Mass Spectrometry Reveals Protein Kinase CK2 High-Order Oligomerization via the Circular and Linear Assembly.Predicting CK2 beta-dependent substrates using linear patterns.Identification of Candidate Casein Kinase 2 Substrates in Mitosis by Quantitative Phosphoproteomics.Therapeutic targeting of CK2 in acute and chronic leukemias.
P2860
Q26750653-A42646AC-B3BC-4189-9F23-DA93FC16CFEFQ27026335-2B7EA1CF-EDE3-4003-BC4E-BB068A435F40Q27332192-EA732D47-F0B0-4993-BE1B-3A458B312D84Q33524570-3D5D6E2D-55F2-4A9F-AFEC-092517F2BDCFQ33532734-BCB2A531-3F68-41B1-9AD9-02D65C851544Q34122676-33FE29C6-AC56-401C-A2D4-BEFA4517CF33Q34265716-AEDC9F3E-E5E2-4D7B-AAED-9D8575C6D3E8Q35270830-C81CF887-3966-4D7C-90CB-F5757A6E52F0Q35423247-2C5A696A-5C57-49A1-A2CA-EC060D90C8A5Q35577635-8C75AA98-4338-43E2-94E3-CF87FD080B3FQ35857057-503C6B06-AAD9-49F0-8EA0-14F548F49CD8Q35995567-C454E0DD-F492-444D-8ABC-A21CAF5BE340Q36244285-3201AD35-4924-462C-B29E-70D230BC567EQ36263671-CC595467-5BF4-4A12-BB03-A509D8834E0AQ36312671-F104F684-FF08-4A06-B46C-27F636686E43Q37487082-3437D50C-1632-4C52-A5A8-4CD5112A5F80Q38211598-18646BDC-1575-4F7C-B834-4DB8DEE758C7Q38365378-D9E7EE38-2FB4-49DE-B757-79ABCB27A91DQ38632634-2DE8CE2B-1550-432C-A569-6241B4B5EEE8Q38820266-E29CF702-552E-4CE9-99F6-D9A9099B5E4AQ39168849-E628B1F1-2E50-4A3F-966F-238FEB4ECE78Q39381625-B47E618D-D395-440D-A700-540F7885B6FBQ46576409-80777187-D590-4995-B315-1B7DE91F7F8EQ47137966-A38243F2-E746-4784-9BA7-3BC8707ED62CQ47158890-9F597C0F-39BF-4FC0-B010-2ADE4BB6C955Q47677919-DF942408-D6B8-4F71-8A0C-2F95C393E386
P2860
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
CIGB-300, a novel proapoptotic ...... ies both in vitro and in vivo.
@ast
CIGB-300, a novel proapoptotic ...... ies both in vitro and in vivo.
@en
type
label
CIGB-300, a novel proapoptotic ...... ies both in vitro and in vivo.
@ast
CIGB-300, a novel proapoptotic ...... ies both in vitro and in vivo.
@en
prefLabel
CIGB-300, a novel proapoptotic ...... ies both in vitro and in vivo.
@ast
CIGB-300, a novel proapoptotic ...... ies both in vitro and in vivo.
@en
P2093
P50
P1476
CIGB-300, a novel proapoptotic ...... ies both in vitro and in vivo.
@en
P2093
Agueda Santana
Alina Díaz
Aniel Sanchez
Arielis Rodriguez
Boris Acevedo
Carlos López
Carmen Valenzuela
Dania Bacardi
Ernesto López
Hernán Farina
P2888
P304
P356
10.1007/S11010-008-9814-5
P577
2008-06-25T00:00:00Z
P5875
P6179
1003036322